Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly reported FY 2025 revenue of approximately $65.2 billion, up 44.7%, and net income of $20.6 billion, while Novo Nordisk posted revenue of $46.4 billion, up 6.4%, and net income of $15.4 billion. Lilly leads on reported growth and operating margin (49.7% versus Novo’s 45.4%); Novo offers a 4.8% dividend yield versus Lilly’s 0.6% and trades at lower valuations, including forward P/E ratios of 11.1x versus 31.2x. The article favors Lilly for growth and its planned next-generation oral weight-loss drugs, while identifying Novo as more attractive for income and valuation.

Analysis

The key equity question is whether supply-constrained GLP-1 growth is becoming a durable earnings gap or whether expectations have outrun what manufacturing, reimbursement, and patient persistence can support. Lilly’s premium leaves less room for execution slippage; oral formulations could broaden access, but may also shift demand from higher-value injectables and require substantial capacity. Track net realized pricing and refill persistence, not just prescriptions or launch claims.

Novo’s discount could narrow if supply availability and U.S. access improve, but its lower multiple is not automatically mispricing: slower growth and competitive share loss may justify it. The article’s financial comparisons are internally inconsistent across sections and periods, and the valuation data lack a common source/date. Verify comparable reported revenue, guidance, consensus estimates, and current prices before sizing any relative-value position. Near term, prescription and supply updates can move the spread; over 1–3 months, earnings, capacity commentary, and payer terms matter; over 6–18 months, oral uptake, competitor launches, and pricing policy determine whether the growth premium persists. Distributors may see more throughput, but higher GLP-1 volume alone does not establish meaningful incremental earnings given their role and economics.

Key Decisions for Investors

• Prefer a small, risk-controlled NVO-over-LLY relative-value position only if current comparable forward estimates confirm the valuation gap and NVO’s supply/access indicators stabilize. The thesis is multiple convergence, not that NVO will match Lilly’s growth. Reassess or exit if NVO guides down, loses share, or the gap reflects persistently weaker earnings.
• Avoid chasing LLY solely on oral-drug optionality. Add only after evidence of durable refill rates, net pricing, and manufacturing capacity; trim if guidance or prescription trends weaken while the valuation premium remains elevated.
• Monitor U.S. prescription/refill trends, supply availability, payer coverage and net price, plus each company’s capacity and guidance at the next results. These are the catalysts; the article does not establish that either company has an imminent earnings inflection.
• Do not trade CAH, COR, or MCK as direct GLP-1 beneficiaries without evidence of incremental distribution profit or a material change in their economics. Higher product volume may not translate proportionally into earnings.